

Robert Baughman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9513343/robert-baughman-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284
papers

16,416
citations

66
h-index

119
g-index

312
ext. papers

19,655
ext. citations

4.8
avg, IF

6.61
L-index

#	Paper	IF	Citations
284	Clinical characteristics of patients in a case control study of sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 1885-9	10.2	1081
283	Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. <i>Lancet, The</i> , 1998 , 351, 929-933	40	599
282	An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1004-14	10.2	593
281	Sarcoidosis. <i>Lancet, The</i> , 2003 , 361, 1111-8	40	543
280	Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 795-802	10.2	480
279	Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. <i>New England Journal of Medicine</i> , 1996 , 334, 1417-21	59.2	460
278	Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 193-6	10.2	443
277	A case control etiologic study of sarcoidosis: environmental and occupational risk factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 1324-30	10.2	441
276	A concise review of pulmonary sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 573-81	10.2	323
275	Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 2085-91	10.2	315
274	Bronchoalveolar lavage for diagnosing acute bacterial pneumonia. <i>Journal of Infectious Diseases</i> , 1987 , 155, 855-61	7	274
273	The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014 , 31, 19-27	1.1	213
272	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, e26-e51	10.2	202
271	Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. <i>European Respiratory Journal</i> , 2008 , 31, 1189-96	13.6	193
270	Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1999 , 16, 75-86	1.1	185
269	Thrombocytopenia in the intensive care unit. <i>Chest</i> , 1993 , 104, 1243-7	5.3	181
268	Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. <i>Chest</i> , 2010 , 138, 1078-85	5.3	159

267	Thalidomide for chronic sarcoidosis. <i>Chest</i> , 2002 , 122, 227-32	5.3	159
266	Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2000 , 17, 60-6	1.1	157
265	Genetic variation among <i>Pneumocystis carinii</i> hominis isolates in recurrent pneumocystosis. <i>Journal of Infectious Diseases</i> , 1995 , 172, 595-8	7	154
264	Etanercept for Refractory Ocular Sarcoidosis. <i>Chest</i> , 2005 , 128, 1062-1067	5.3	148
263	Sarcoidosis in America. Analysis Based on Health Care Use. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 1244-52	4.7	147
262	Six-minute walk test and health status assessment in sarcoidosis. <i>Chest</i> , 2007 , 132, 207-13	5.3	143
261	The diagnostic pathway to sarcoidosis. <i>Chest</i> , 2003 , 123, 406-12	5.3	140
260	Use of the protected specimen brush in patients with endotracheal or tracheostomy tubes. <i>Chest</i> , 1987 , 91, 233-6	5.3	138
259	Infliximab for refractory sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2001 , 18, 70-4	1.1	138
258	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. <i>JAMA Neurology</i> , 2018 , 75, 1546-1553	17.2	136
257	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>European Respiratory Journal</i> , 2014 , 44, 1296-307	13.6	126
256	Treatment of sarcoidosis. <i>Clinics in Chest Medicine</i> , 2008 , 29, 533-48, ix-x	5.3	121
255	Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996 , 154, 76-81	10.2	117
254	The use of low dose methotrexate in refractory sarcoidosis. <i>American Journal of the Medical Sciences</i> , 1990 , 299, 153-7	2.2	117
253	Pulmonary sarcoidosis. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 389-402	35.1	113
252	Decreased surfactant protein A in patients with bacterial pneumonia. <i>The American Review of Respiratory Disease</i> , 1993 , 147, 653-7		113
251	Racial difference in sarcoidosis mortality in the United States. <i>Chest</i> , 2015 , 147, 438-449	5.3	108
250	Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. <i>Current Opinion in Pulmonary Medicine</i> , 2013 , 19, 515-61	3	105

249	Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. <i>Chest</i> , 2014 , 145, 810-817	5.3	104
248	Two year prognosis of sarcoidosis: the ACCESS experience. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2003 , 20, 204-11	1.1	101
247	A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006 , 23, 201-8	1.1	101
246	Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007 , 28, 475-85	3.9	99
245	Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. <i>Translational Research</i> , 1990 , 115, 36-42		97
244	Presenting characteristics as predictors of duration of treatment in sarcoidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006 , 99, 307-15	2.7	92
243	Depression in sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 163, 329-34	10.2	92
242	Molecular genetic distinction of <i>Pneumocystis carinii</i> from rats and humans. <i>Journal of Eukaryotic Microbiology</i> , 1993 , 40, 733-41	3.6	92
241	Rituximab in the treatment of refractory pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2014 , 43, 1525-8	13.6	91
240	Use of bronchoalveolar lavage to diagnose bacterial pneumonia in mechanically ventilated patients. <i>Critical Care Medicine</i> , 1990 , 18, 169-73	1.4	91
239	The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. <i>The American Review of Respiratory Disease</i> , 1990 , 142, 1268-71		89
238	New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 813-22	35.1	87
237	Genome-wide search for sarcoidosis susceptibility genes in African Americans. <i>Genes and Immunity</i> , 2005 , 6, 509-18	4.4	87
236	A clinical approach to the use of methotrexate for sarcoidosis. <i>Thorax</i> , 1999 , 54, 742-6	7.3	87
235	Predictors of Mortality in Pulmonary Sarcoidosis. <i>Chest</i> , 2018 , 153, 105-113	5.3	86
234	Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. <i>Chest</i> , 1991 , 99, 92-7	5.3	86
233	Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit. <i>Clinical Infectious Diseases</i> , 2008 , 46 Suppl 4, S296-334; quiz 335-8	11.6	85
232	Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. <i>Chest</i> , 2005 , 128, 1062-47	5.3	85

231	Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy. <i>The American Review of Respiratory Disease</i> , 1984 , 129, 676-81		82
230	Established and experimental medical therapy of pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2013 , 41, 1424-38	13.6	80
229	The continuing utility of bronchoalveolar lavage to diagnose opportunistic infection in AIDS patients. <i>American Journal of Medicine</i> , 1994 , 97, 515-22	2.4	78
228	Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2011 , 28, 56-64	1.1	76
227	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014 , 69, 428-36	7.3	75
226	Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. <i>Chest</i> , 2009 , 136, 526-535	5.3	74
225	Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. <i>Chest</i> , 1992 , 102, 1090-4	5.3	73
224	Infliximab in chronic ocular inflammation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005 , 43, 7-11	2	73
223	Pulmonary sarcoidosis. <i>Clinics in Chest Medicine</i> , 2004 , 25, 521-30, vi	5.3	70
222	Liver-test abnormalities in sarcoidosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 17-24	2.2	69
221	Fatigue in sarcoidosis: a systematic review. <i>Current Opinion in Pulmonary Medicine</i> , 2009 , 15, 499-506	3	68
220	Double-blind, randomized trial of dexamethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. <i>Chest</i> , 2008 , 133, 1189-95	5.3	68
219	Inhaled iloprost for sarcoidosis associated pulmonary hypertension. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2009 , 26, 110-20	1.1	66
218	Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. <i>Archives of Dermatology</i> , 2012 , 148, 262-4		65
217	Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). <i>Journal of Occupational and Environmental Medicine</i> , 2005 , 47, 226-34	2	63
216	Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. <i>The American Review of Respiratory Disease</i> , 1992 , 145, 1226-9		62
215	Practical eminence and experience-based recommendations for use of TNF- β inhibitors in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014 , 31, 91-107	1.1	62
214	Ocular sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010 , 31, 452-62	3.9	61

213	Pulmonary hypertension in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006 , 23, 108-16	1.1	61
212	Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. <i>Chest</i> , 2017 , 151, 139-148	5.3	60
211	Rheumatologic manifestations of sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010 , 31, 463-73	3.9	60
210	Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. <i>BioDrugs</i> , 2003 , 17, 425-31	7.9	59
209	Fungal infections as a complication of therapy for sarcoidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005 , 98, 451-6	2.7	58
208	Treatment of Sarcoidosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015 , 49, 79-92	12.3	55
207	Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis. <i>Journal of Intensive Care Medicine</i> , 2003 , 18, 269-74	3.3	55
206	Predicting respiratory failure in sarcoidosis patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1997 , 14, 154-8	1.1	55
205	Steroid-sparing alternative treatments for sarcoidosis. <i>Clinics in Chest Medicine</i> , 1997 , 18, 853-64	5.3	54
204	Calcium and vitamin D metabolism in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2013 , 30, 113-20	1.1	54
203	Cardiac involvement in sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002 , 23, 513-27	3.9	52
202	ERS clinical practice guidelines on treatment of sarcoidosis. <i>European Respiratory Journal</i> , 2021 ,	13.6	52
201	Clinical characteristics of patients with bone sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 143-148	5.3	51
200	Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. <i>Journal of Pain and Symptom Management</i> , 2013 , 45, 159-69	4.8	50
199	Evidence-based therapy for cutaneous sarcoidosis. <i>Clinics in Dermatology</i> , 2007 , 25, 334-40	3	48
198	Diagnosis and management of neurological sarcoidosis. <i>Archives of Internal Medicine</i> , 1997 , 157, 1864-8		48
197	Nasal and sinus manifestations of sarcoidosis. <i>American Journal of Rhinology & Allergy</i> , 2000 , 14, 157-61		47
196	Utility of bronchoalveolar lavage in assessing pneumonia in immunosuppressed renal transplant recipients. <i>American Journal of Medicine</i> , 1993 , 95, 358-64	2.4	47

195	Use of fluticasone in acute symptomatic pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2002 , 19, 198-204	1.1	47
194	Endpoints for clinical trials of sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2012 , 29, 90-8	1.1	47
193	A Single US Center Experience of Transbronchial Lung Cryobiopsy for Diagnosing Interstitial Lung Disease With a 2-Scope Technique. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2017 , 24, 131-135	1.8	46
192	Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT). <i>Thorax</i> , 2010 , 65, 181-6	7.3	46
191	Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014 , 31, 46-54	1.1	46
190	Repository corticotropin for Chronic Pulmonary Sarcoidosis. <i>Lung</i> , 2017 , 195, 313-322	2.9	45
189	Treatment of sarcoidosis: grading the evidence. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 677-683	3.8	44
188	Therapy for sarcoidosis: evidence-based recommendations. <i>Expert Review of Clinical Immunology</i> , 2012 , 8, 95-103	5.1	44
187	Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. <i>Lung</i> , 1987 , 165, 371-7	2.9	44
186	Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. <i>Respiratory Medicine</i> , 2013 , 107, 2009-13	4.6	43
185	Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. <i>Chest</i> , 2013 , 143, 461-470	5.3	43
184	Ocular manifestations of sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002 , 23, 543-8	3.9	43
183	Management of extrapulmonary sarcoidosis: challenges and solutions. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 1623-1634	2.9	42
182	Chronic pulmonary aspergillosis complicating sarcoidosis. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	41
181	A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. <i>Respiratory Medicine</i> , 2016 , 110, 66-72	4.6	41
180	Rituximab for refractory granulomatous eye disease. <i>Clinical Ophthalmology</i> , 2012 , 6, 1613-8	2.5	41
179	Prolonged use of methotrexate for sarcoidosis. <i>Archives of Internal Medicine</i> , 1995 , 155, 846-51		41
178	Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1999 , 16, 57-61	1.1	41

177	Therapeutic options for sarcoidosis: new and old. <i>Current Opinion in Pulmonary Medicine</i> , 2002 , 8, 464-9	3	40
176	The anemia of sarcoidosis. <i>Sarcoidosis</i> , 1988 , 5, 51-5		40
175	Bone health issues in sarcoidosis. <i>Current Rheumatology Reports</i> , 2011 , 13, 265-72	4.9	39
174	Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. <i>Archives of Internal Medicine</i> , 2003 , 163, 615-20		39
173	Protected-specimen brush technique in the diagnosis of ventilator-associated pneumonia. <i>Chest</i> , 2000 , 117, 203S-206S	5.3	39
172	Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. <i>Vaccine Journal</i> , 2011 , 18, 931-9		38
171	The use of carbapenems in the treatment of serious infections. <i>Journal of Intensive Care Medicine</i> , 2009 , 24, 230-41	3.3	38
170	Pulmonary and psychosocial findings at enrollment in the ACCESS study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2005 , 22, 147-53	1.1	38
169	Management of neurosarcoidosis: a clinical challenge. <i>Current Opinion in Neurology</i> , 2019 , 32, 475-483	7.1	37
168	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i> , 2012 , 142, e1S-e111S	5.3	37
167	Role of bronchoalveolar lavage in interstitial lung disease. <i>Clinics in Chest Medicine</i> , 2001 , 22, 331-41	5.3	37
166	The lung in the immunocompromised patient. Infectious complications Part 1. <i>Respiration</i> , 1999 , 66, 95-109	1.1	37
165	Increased <i>Pneumocystis carinii</i> recovery from the upper lobes in <i>Pneumocystis pneumonia</i> . The effect of aerosol pentamidine prophylaxis. <i>Chest</i> , 1993 , 103, 426-32	5.3	37
164	Management of ocular sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2012 , 29, 26-33	1.1	37
163	Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. <i>European Respiratory Review</i> , 2020 , 29,	9.8	36
162	Comparison of sarcoidosis phenotypes among affected African-American siblings. <i>Chest</i> , 2006 , 130, 855-63	5.3	35
161	Six-minute walk test in managing and monitoring sarcoidosis patients. <i>Current Opinion in Pulmonary Medicine</i> , 2007 , 13, 439-44	3	34
160	Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome.. <i>Clinical Chemistry</i> , 1984 , 30, 521-523	5.5	34

159	Pulmonary manifestations of sarcoidosis. <i>Presse Medicale</i> , 2012 , 41, e289-302	2.2	33
158	Therapeutic approach of hepatic sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2012 , 18, 472-82	3	33
157	Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. <i>Clinical Pulmonary Medicine</i> , 2016 , 23, 67-75	0.3	32
156	Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. <i>Respiratory Medicine</i> , 2018 , 139, 72-78	4.6	32
155	The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. <i>Respiratory Medicine</i> , 2014 , 108, 189-94	4.6	31
154	Pulmonary hypertension associated with sarcoidosis. <i>Arthritis Research and Therapy</i> , 2007 , 9 Suppl 2, S8	5.7	31
153	Effects of sarcoid and steroids on angiotensin-converting enzyme. <i>The American Review of Respiratory Disease</i> , 1983 , 128, 631-3		31
152	Pulmonary Hypertension in Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015 , 36, 703-14	5.3	30
151	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	30
150	Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. <i>American Journal of Clinical Dermatology</i> , 2004 , 5, 385-94	7.1	29
149	Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 955-964	10.2	29
148	Diagnosis and management of spinal cord sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006 , 23, 58-65	1.1	29
147	Leflunomide for chronic sarcoidosis. <i>Order</i> , 2004 , 21, 43-8	0.5	28
146	Effect of obesity on patient-reported outcomes in sarcoidosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013 , 17, 559-64	2.1	27
145	Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. <i>American Journal of Clinical Dermatology</i> , 2008 , 9, 155-61	7.1	27
144	Difficult treatment issues in sarcoidosis. <i>Journal of Internal Medicine</i> , 2003 , 253, 41-5	10.8	27
143	Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. <i>Pulmonary Circulation</i> , 2016 , 6, 557-562	2.7	27
142	Biologic therapies in the treatment of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 817-25.1		27

141	Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. <i>Respiratory Medicine</i> , 2018 , 140, 71-76	4.6	27
140	Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of Mycobacterium tuberculosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2008 , 25, 93-9	1.1	27
139	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2431-2448	4	26
138	Clinical phenotypes in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2014 , 20, 496-502	3	26
137	Systemic evaluation of a potential cutaneous sarcoidosis patient. <i>Clinics in Dermatology</i> , 2007 , 25, 303-113		26
136	Sarcoidosis. Usual and unusual manifestations. <i>Chest</i> , 1988 , 94, 165-70	5.3	26
135	Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1878-1901	15.1	26
134	Fatigue in sarcoidosis: American versus Dutch patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2009 , 26, 92-7	1.1	26
133	High-Risk Sarcoidosis. Current Concepts and Research Imperatives. <i>Annals of the American Thoracic Society</i> , 2017 , 14, S437-S444	4.7	25
132	Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. <i>Clinics in Dermatology</i> , 2007 , 25, 341-6	3	25
131	Right and left ventricular function at rest and with exercise in patients with sarcoidosis. <i>Chest</i> , 1984 , 85, 301-6	5.3	25
130	Sarcoidosis: patient treatment priorities. <i>ERJ Open Research</i> , 2018 , 4,	3.5	25
129	Breast disease in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2001 , 18, 301-6	1.1	25
128	The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis. <i>Respiratory Medicine</i> , 2017 , 131, 65-69	4.6	24
127	Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. <i>Clinics in Chest Medicine</i> , 2010 , 31, 565-88	5.3	24
126	Use of bronchoalveolar lavage semiquantitative cultures in cystic fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997 , 156, 286-91	10.2	24
125	Diagnosis of ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2003 , 9, 397-402	3.5	24
124	Sarcoidosis Diagnostic Score: A Systematic Evaluation to Enhance the Diagnosis of Sarcoidosis. <i>Chest</i> , 2018 , 154, 1052-1060	5.3	23

123	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. <i>Current Respiratory Medicine Reviews</i> , 2015 , 11, 163-174	0.3	23
122	Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2016 , 32, 289-95	1.1	23
121	Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?. <i>Lung</i> , 2013 , 191, 43-52	2.9	22
120	Medical therapy of sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 391-406	3.9	22
119	Current concepts regarding calcium metabolism and bone health in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2017 , 23, 476-481	3	21
118	Sarcoidosis-Associated Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 450-462	3.9	21
117	Ventilator associated pneumonia: quality of nonbronchoscopic bronchoalveolar lavage sample affects diagnostic yield. <i>European Respiratory Journal</i> , 2000 , 16, 1152-7	13.6	20
116	Follow-up bronchoalveolar lavage in AIDS patients with <i>Pneumocystis carinii</i> pneumonia. <i>Pneumocystis carinii</i> burden predicts early relapse. <i>The American Review of Respiratory Disease</i> , 1991 , 143, 1067-71		20
115	Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015 , 32, 106-14	1.1	20
114	Real-time quantitative reverse transcription-polymerase chain reaction to detect propionibacterial ribosomal RNA in the lymph nodes of Chinese patients with sarcoidosis. <i>Clinical and Experimental Immunology</i> , 2015 , 181, 511-7	6.2	19
113	Advanced sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019 , 25, 497-504	3	19
112	Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry. <i>PLoS ONE</i> , 2011 , 6, e29126	3.7	17
111	Novel therapies for sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007 , 28, 128-33	3.9	17
110	Short-Term Particulate Air Pollution Exposure is Associated with Increased Severity of Respiratory and Quality of Life Symptoms in Patients with Fibrotic Sarcoidosis. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	17
109	Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?. <i>Journal of Rheumatology</i> , 2007 , 34, 2129-31	4.1	17
108	Features of sarcoidosis associated with chronic disease. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015 , 31, 275-81	1.1	17
107	The use of an indirect fluorescent antibody test for detecting <i>Pneumocystis carinii</i> . <i>Archives of Pathology and Laboratory Medicine</i> , 1989 , 113, 1062-5	5	16
106	Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield. <i>Respirology</i> , 2019 , 24, 531-542	3.6	15

105	Use of a rapid differential stain for identifying <i>Pneumocystis carinii</i> in bronchoalveolar lavage fluid. Diagnostic efficacy in patients with AIDS. <i>Chest</i> , 1989 , 95, 494-7	5.3	15
104	Prevalence of digital clubbing in bronchogenic carcinoma by a new digital index. <i>Clinical and Experimental Rheumatology</i> , 1998 , 16, 21-6	2.2	15
103	Combination therapy for sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2001 , 18, 133-7	1.1	15
102	Neuro-ophthalmic sarcoidosis. <i>Eye and Brain</i> , 2012 , 4, 13-25	5.7	14
101	Tumor Necrosis Factor inhibition in treating sarcoidosis: the American Experience. <i>Revista Portuguesa De Pneumologia</i> , 2007 , 13, S47-S50		14
100	Therapy for extrapulmonary sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002 , 23, 589-96	3.9	14
99	Lobar pentamidine levels and <i>Pneumocystis carinii</i> pneumonia following aerosolized pentamidine. <i>Chest</i> , 1994 , 105, 53-6	5.3	14
98	Semiquantitative technique for estimating <i>Pneumocystis carinii</i> burden in the lung. <i>Journal of Clinical Microbiology</i> , 1990 , 28, 1425-7	9.7	14
97	Clinical phenotyping: role in treatment decisions in sarcoidosis. <i>European Respiratory Review</i> , 2020 , 29,	9.8	14
96	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , 2019 , 197, 427-436	2.9	13
95	A Circulating MicroRNA Signature Serves as a Diagnostic and Prognostic Indicator in Sarcoidosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018 , 58, 40-54	5.7	13
94	Clinical management of pulmonary sarcoidosis. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 577-91	3.8	13
93	Treatment Modalities for Sarcoidosis. <i>Clinical Pulmonary Medicine</i> , 1994 , 1, 223-231	0.3	13
92	Diagnosis of ventilator-associated pneumonia. <i>Microbes and Infection</i> , 2005 , 7, 262-7	9.3	12
91	Diagnostic strategies in <i>Pneumocystis carinii</i> pneumonia. <i>Frontiers in Bioscience - Landmark</i> , 1998 , 3, e1-128		12
90	Alternatives to corticosteroids in the treatment of sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1997 , 14, 121-30	1.1	12
89	Sarcoidosis: is therapy effective?. <i>Seminars in Respiratory Infections</i> , 1998 , 13, 255-73		12
88	Sarcoidosis extent relates to molecular variability. <i>Clinical and Experimental Immunology</i> , 2017 , 188, 444-454		11

87	Systemic immune response of patients with active pulmonary sarcoidosis. <i>Clinical and Experimental Immunology</i> , 1985 , 61, 535-41	6.2	10
86	Methotrexate for sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1998 , 15, 147-9	1.1	10
85	First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000394	5.6	9
84	Surfactant replacement for ventilator-associated pneumonia: a preliminary report. <i>Respiration</i> , 2002 , 69, 57-62	3.7	9
83	Spontaneous hydrogen peroxide release from alveolar macrophages of patients with active sarcoidosis: comparison with cigarette smokers. <i>Translational Research</i> , 1988 , 111, 399-404		9
82	Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, e2020009	1.1	9
81	Worsening of pulmonary sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2014 , 20, 508-16	3	8
80	Antibiotic resistance in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2002 , 8, 430-4	3.5	8
79	COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. <i>Frontiers in Medicine</i> , 2021 , 8, 672028	4.9	8
78	Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021 , 11,	3.8	8
77	Evaluating the Minimal Clinically Important Difference of the KingB Sarcoidosis Questionnaire in a Multicenter Prospective Study. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 477-485	4.7	8
76	Nonsteroidal therapy for idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2001 , 7, 309-13	3	7
75	Lung derived surface active material (SAM) inhibits natural killer cell tumor cytotoxicity. <i>Journal of Clinical & Laboratory Immunology</i> , 1989 , 28, 51-4		7
74	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel. <i>Respiratory Medicine Case Reports</i> , 2016 , 17, 5-7	1.2	6
73	Accuracy of Serial PET-CT Imaging in Systemic Sarcoidosis. <i>Journal of Clinical Imaging Science</i> , 2014 , 4, 21	1.1	6
72	Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i> , 2012 , 142, 1284-1288	5.3	6
71	Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 87-98	1.1	6
70	Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. <i>Chest</i> , 2021 , 159, 1902-1912	5.3	6

69	Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. <i>European Respiratory Review</i> , 2020 , 29,	9.8	6
68	The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. <i>Respiratory Medicine</i> , 2021 , 187, 106564	4.6	6
67	Can persistent tumor necrosis factor release lead to refractory sarcoidosis?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2002 , 19, 164-6	1.1	6
66	Use of third-line therapies in advanced sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 834-840	2.2	6
65	Clinical trials in pulmonary sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2015 , 21, 525-31	3	5
64	Sarcoidosis. <i>Clinics in Dermatology</i> , 2007 , 25, 231	3	5
63	Microbiologic diagnosis of ventilator-associated pneumonia. <i>Clinics in Chest Medicine</i> , 2005 , 26, 81-6	5.3	5
62	Advanced Pulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 700-715	3.9	5
61	Nonbronchoscopic evaluation of ventilator-associated pneumonia. <i>Seminars in Respiratory Infections</i> , 2003 , 18, 95-102		5
60	The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis. <i>Lung</i> , 2020 , 198, 917-924	2.9	4
59	The variability of sarcoidosis: can we predict it?. <i>Chest</i> , 2003 , 123, 1329-32	5.3	4
58	An inhibitor of tumor necrosis factor found in pleural effusions. <i>Translational Research</i> , 1991 , 118, 326-31		4
57	A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS). <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019 , 36, 86-88	1.1	4
56	Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, e2020001	1.1	4
55	Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. <i>ERJ Open Research</i> , 2019 , 5,	3.5	4
54	Interpretation of the Wright-Giemsa Stained Bronchoalveolar Lavage Specimen. <i>Laboratory Medicine</i> , 2004 , 35, 553-557	1.6	3
53	Pneumonia in Immunocompromised and Immunocompetent Patients Requiring Mechanical Ventilation. <i>Journal of Bronchology</i> , 1999 , 6, 78-83		3
52	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.. <i>European Respiratory Review</i> , 2022 , 31,	9.8	3

51	Current treatment of sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 591-597	3	3
50	Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). <i>Respiratory Medicine</i> , 2021 , 106436	4.6	3
49	Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. <i>Chest</i> , 2021 ,	5.3	3
48	Treatment of sarcoidosis. <i>Panminerva Medica</i> , 2013 , 55, 175-89	2	3
47	Higher Priced Older Pharmaceuticals: How Should We Respond?. <i>Chest</i> , 2018 , 153, 23-33	5.3	2
46	Considerations in the Choice and Administration of Agents for Empiric Antimicrobial Therapy. <i>Surgical Infections</i> , 2005 , 6, s-71-s-82	2	2
45	Extrapulmonary sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002 , 23, 503	3.9	2
44	Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019 , 36, 254-260	1.1	2
43	COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021 , 38, e2021029	1.1	2
42	Management of Advanced Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	2
41	Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 179-210	3.8	2
40	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.. <i>Respiratory Medicine</i> , 2022 , 196, 106801	4.6	2
39	Sarcoidosis: is cryobiopsy not cool enough? - AuthorsReply. <i>Lancet Respiratory Medicine</i> , 2018 , 6, e45	35.1	1
38	Sarcoidosis-associated fatigue: an often forgotten symptom--author reply. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 111	5.1	1
37	The Treatment of Pulmonary Sarcoidosis 2014 , 41-64		1
36	Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010 , 31, 373-4	3.9	1
35	TNF--a antagonists and sarcoidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011 , 104, 374	2.7	1
34	Sarcoidosis Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 462-462	10.2	1

33	Bronchoscopic Evaluation of Moxifloxacin Therapy in Acute Exacerbations of Chronic Bronchitis Previously Treated With Azithromycin. <i>Journal of Bronchology</i> , 2007 , 14, 144-148		1
32	Diffuse Lung Disease491-508		1
31	Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.. <i>Pulmonary Therapy</i> , 2022 , 8, 43	3	1
30	Generalized immune response to <i>Pneumocystis carinii</i> infection in the lung. <i>Journal of Protozoology</i> , 1991 , 38, 1875-1885		1
29	Isolation of functionally active pleural macrophages. <i>Journal of Clinical & Laboratory Immunology</i> , 1989 , 30, 147-51		1
28	Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Detection of Sarcoidosis. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1510-1515	4.7	1
27	Advances in predicting patient survival in pulmonary sarcoidosis. <i>Expert Opinion on Orphan Drugs</i> , 2021 , 9, 113-122	1.1	1
26	The Value of a Patient Global Assessment in Management of Sarcoidosis. <i>Lung</i> , 2021 , 199, 357-362	2.9	1
25	Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT. <i>Frontiers in Medicine</i> , 2021 , 8, 595077	4.9	1
24	Diagnosis of Pneumonia in Immunocompromised Patient53-93		1
23	The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP).. <i>Respiratory Medicine</i> , 2022 , 196, 106819	4.6	1
22	Roflumilast (Daliresp [®]) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021 , 38, e2021035	1.1	1
21	New Therapies for Sarcoidosis. <i>Clinical Pulmonary Medicine</i> , 2004 , 11, 154-160	0.3	0
20	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017 , 34, 165-169	1.1	0
19	Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. <i>BMC Pulmonary Medicine</i> , 2021 , 21, 365	3.5	0
18	Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray.. <i>BMC Pulmonary Medicine</i> , 2022 , 22, 146	3.5	0
17	Chest CT scan: The best predictor of mortality in advanced pulmonary sarcoidosis?. <i>Respiratory Medicine</i> , 2020 , 170, 106059	4.6	
16	Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment 2017 , 129-143		

- 15 Is Pulmonary Hypertension Without Left Ventricular Dysfunction Associated With Poor Survival in Patients With Sarcoidosis or Is It Just a Factor of Advanced Disease Stage?: Response. *Chest*, **2011**, 139, 970-971 5.3
- 14 Health Effects of Nanoparticles (Inhalation) from Medical Point of View/Type of Diseases **2010**, 187-202
- 13 Complicated Sarcoidosis: Challenges in Dealing with Severe Manifestations **2011**, 201-219
- 12 Pneumonia in the Immunocompromised Patient **2006**, 581-587
- 11 Infliximab Therapy in Pulmonary Sarcoidosis. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 417a-418 10.2
- 10 Identification of bio-markers in sarcoidosis BAL using multidimensional Differential Display Proteome Analysis coupled with nano-HPLC tandem mass spectrometry. *Revista Portuguesa De Pneumologia*, **2007**, 13, S35-S39
- 9 Bronchoalveolar Lavage in Interstitial Lung Disease. *Lung Biology in Health and Disease*, **2003**, 253-272
- 8 Sino-Nasal Sarcoidosis **2018**, 137-152
- 7 Drug Therapy for Interstitial Lung Disease **2012**, 101-120
- 6 Cardiac sarcoidosis: worse pulmonary function due to left ventricular ejection fraction?: A case-control study. *Medicine (United States)*, **2019**, 98, e18037 1.8
- 5 Response. *Chest*, **2018**, 153, 1507-1508 5.3
- 4 The lung in autoimmune diseases: sarcoidosis. *Handbook of Systemic Autoimmune Diseases*, **2022**, 169-188.3
- 3 Sarcoidosis: principles of diagnosis **2022**, 57-74
- 2 The calcium-kidney-bone axis in sarcoidosis **2022**, 193-205
- 1 Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2022**, 38, e2021032 1.1